IDT Sample Clauses

IDT. In August 2010, we entered into a license agreement with Integrated DNA Technologies, or IDT, related to the use of blocked primers in combination with HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 90 days’ notice. The license is exclusive to the fields of amplification utilizing HDA and detection of diagnostic targets in human in-vitro diagnostic testing, but is non-exclusive to all oncology and human papilloma virus targets or markers. These technologies have resulted in four pending U.S. patent applications and one issued European patent. We pay a royalty fee for the license of this technology based on a percentage of our “Net Sales” of products using these technologies (as defined in the license agreement). Schedule 3(v)(v) See Schedule 3(v)(i). Schedule 3(w) – Absence of Litigation Wrongful termination complaint filed in the United States District Court in and for the District of Utah, Central Division by a former employee, Xxxxxxxxx Xxxxxx, against Great Basin Scientific, Inc. on June 15, 2016. Schedule 3(aa)(i) - Intellectual Property Rights Great Basin Owned Patents Patent Title U.S. 8,637,250 Systems and methods for point of care amplification and detection of nucleic acids (HDA, methods) US 14/108,630 Systems and methods for point of care amplification and detection of nucleic acids (continuation, HDA, kit claims) CA2715890 Systems and methods for point of care amplification and detection of nucleic acids (general method) EP2245184 Systems and methods for point of care amplification and detection of nucleic acids (HDA) EP15182599.9 (divisional from ‘84) Systems and methods for point of care amplification and detection of nucleic acids (general method) EP08853920.0 Methods and compositions for amplifying a detectable signal U.S. 8,574,833 Methods and compositions for amplifying a detectable signal (nucleic acid targets, methods/kits/system) US 9,200,312 Methods and compositions for amplifying a detectable signal (continuation, generalize target, kit/system) US 9,359,637 Methods and compositions for amplifying a detectable signal (continuation, generalize target, methods of use/prep) US 14/949,240 Methods and compositions for amplifying a detectable signal (continuation, generalize target, methods of use/prep) CA2705984 Methods and compositions for amplifying a detectable signal US 13/911,878 Analyzer and Disposable...
Sample 1
AutoNDA by SimpleDocs
IDT. In August 2010, we entered into a license agreement with Integrated DNA Technologies, or IDT, related to the use of blocked primers in combination with HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 90 days’ notice. The license is exclusive to the fields of amplification utilizing HDA and detection of diagnostic targets in human in-vitro diagnostic testing, but is non-exclusive to all oncology and human papilloma virus targets or markers. These technologies have resulted in four pending U.S. patent applications and one issued European patent. We pay a royalty fee for the license of this technology based on a percentage of our “Net Sales” of products using these technologies (as defined in the license agreement). Schedule 4(d) - Use of Proceeds Net proceeds will be used for general operating purposes. Schedule 7(v)
Sample 1
IDT. IDT will maintain, at all times during the Term of this Agreement and for a period of [***] thereafter, a general third party liability insurance including Products liability insurance policy, with a per claim limit of at least [***], and an aggregate limit of at least [***]. In addition, IDT shall maintain an environmental liability insurance policy in accordance with the EU Directive 2004/35/EC, as amended. Without limiting the preceding sentence, IDT shall provide Valneva with at least [***] Notice prior to termination of or reduction in said coverage.
Sample 1
IDT. Phase 2. The attacker runs A2 on the input of state and the output of the challenger. A2 can make the same kinds of query as those in Phase 1. But A2 is not allowed to make a Reveal query on the input of Πt or its partner oracle. A2 terminates by outputting a guess bit b′. Suppose that there are x aborted oracles at the end of the game where x < m . The attacker’s advantage in this game is defined to be AdvA(U )= ′( n−1 t F x, Pr(b = b′)), where the function F′ is defined as follows: on the input of an integer a (a < n) and a value b (0 ≤ b ≤ 1), F′(a, b) is computed as: ′ ,⎨ 0, if b ≤ 1+Σ a(n−1)+1 pj F Σ −1+ pj (a, b)= , b − a(n 1)+1 j=1 j=1 , otherwise
Sample 1
IDT. Reveal(M), where M is an accepted oracle. A 1 terminates by outputting an accepted oracle Mt and some state infor- mation state.
Sample 1
IDT. In August 2010, we entered into a license agreement with Integrated DNA Technologies, or IDT, related to the use of blocked primers in combination with HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 90 days’ notice. The license is exclusive to the fields of amplification utilizing HDA and detection of diagnostic targets in human in-vitro diagnostic testing, but is non-exclusive to all oncology and human papilloma virus targets or markers. These technologies have resulted in four pending U.S. patent applications and one issued European patent. We pay a royalty fee for the license of this technology based on a percentage of our “Net Sales” of products using these technologies (as defined in the license agreement). Schedule 3(ee) – Internal Accounting and Disclosure Controls As stated in our Form 10-K for the year ended December 31, 2015, we identified a material weakness in our system of internal control over financial reporting relating to processes and controls over properly identifying and accounting for transactions of a complex or non-routine nature. Management also identified certain design deficiencies relating to segregation of duties, review and approval, and verification procedures, primarily resulting from the limited number of our accounting staff available to perform such procedures. Additionally, management identified certain design deficiencies to access over information systems. Management plans to implement a number of initiatives to address the ineffective design of the system of internal control over financial reporting, including but not limited to the following: • Employ additional staff in our finance and accounting department to perform the required tasks to maintain an optimal segregation of duties, review and approval and verification procedures and provide optimal levels of oversight. • Continue to work closely with our independent SOX consultants to help improve the overall design of our system of internal control over financial reporting and promptly remediate any identified weaknesses • Continue to evaluate control procedures on an ongoing basis, and, where possible modify those control procedures to improve oversight. • Continue to engage independent consultants to assist accounting staff with processing transactions and preparing financial statements, especially related to complex transactions. W...
Sample 1
IDT. Phase 2. The attacker runs A2 on the input of state and the output of the challenger. A2 can make the same kinds of query as those in Phase 1. But A2 is not allowed to make a Reveal query on the input of Πt or its partner oracle. A2 terminates by outputting a guess bit bj. Suppose that there are x aborted oracles at the end of the game where x < m . The attacker’s advantage in this game is defined to be AdvA(U ) = j( n−1 t F x, Pr(b = bj)), where the function Fj is defined as follows: on the input of an integer a
Sample 1
AutoNDA by SimpleDocs
IDT. Reveal(Π), where Π is an accepted oracle. A 1 terminates by outputting an accepted oracle Πt and some state infor- mation state.
Sample 1

Related to IDT

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Transnet (i) For legal notices: …………………………………………………… …………………………………………………… …………………………………………………… Fax No. ………… Attention: Group Legal Department

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Cloud Services If You would like to deploy Cloud Services, We grant You and Your Affiliates a non-exclusive, non-transferable, worldwide right to authorize individuals solely within Your and Your Affiliates’ organization (“Users”) to access or exchange data via the Cloud Services during the Term (as defined in Section 8 below), but only for Your own internal business purposes and subject to the terms and conditions of this Agreement and terms associated with the specific Cloud Services contained in the Order and applicable schedule(s). We are not responsible for web pages or servers that are not owned or controlled by Us, even if linked to (including via application programming interfaces) the Cloud Service. We do not endorse any sites on the Internet that are linked through the Cloud Service; such links are provided to You and your Users only as a convenience. In addition, certain third-party providers of ancillary software, hardware or services may require Your agreement to additional or different licence or other terms prior to Your or Your Users’ use of or access to such software, hardware or services. Cloud Services offerings may include a limited-use subscription to on- premise Software as described in the applicable schedule(s), and use of such Software must comply with all licence terms. Under no circumstances may the Cloud Services be used for any illegal or illicit purpose in any geography where the Cloud Services are used. You must: (i) protect the secrecy of Your authorized user IDs and passwords; (ii) notify Us immediately of any unauthorized use of any user ID or password or any other known or suspected breach of security; and (iii) report to Us immediately and use reasonable efforts to stop any copying or distribution of content not authorized by Us. You agree that anyone who inputs a valid user ID and password will be deemed an appropriate User unless and until You notify Us otherwise in writing. Any individual User who has violated this Section may have its account suspended.

  • AMD to the Fixed Interest Account, beginning with the date of such transfer, shall be credited with the Current Rate of Interest under this contract which was in effect on the date the transferred contribution was originally deposited into the Fixed Interest Account under the previous AUL contract.

  • Client Client agrees to indemnify, defend, and shall hold harmless Consultant and /or his agents, and to defend any action brought against said parties with respect to any claim, demand, cause of action, debt or liability, including reasonable attorneys' fees to the extent that such action is based upon a claim that: (i) is true, (ii) would constitute a breach of any of Client's representations, warranties, or agreements hereunder, or (iii) arises out of the negligence or willful misconduct of Client, or any Client Content to be provided by Client and does not violate any rights of third parties, including, without limitation, rights of publicity, privacy, patents, copyrights, trademarks, trade secrets, and/or licenses.

  • Logistics The Licensee shall be responsible for:

  • IBM Credit may in its sole discretion from time to time decide the amount of credit IBM Credit extends to Customer, notwithstanding any prior course of conduct between IBM Credit and Customer. IBM Credit may combine all of its advances to make one debt owed by Customer.

  • Telemedicine Services This plan covers clinically appropriate telemedicine services when the service is provided via remote access through an on-line service or other interactive audio and video telecommunications system in accordance with R.I. General Law § 27-81-1. Clinically appropriate telemedicine services may be obtained from a network provider, and from our designated telemedicine service provider. When you seek telemedicine services from our designated telemedicine service provider, the amount you pay is listed in the Summary of Medical Benefits. When you receive a covered healthcare service from a network provider via remote access, the amount you pay depends on the covered healthcare service you receive, as indicated in the Summary of Medical Benefits. For information about telemedicine services, our designated telemedicine service provider, and how to access telemedicine services, please visit our website or contact our Customer Service Department.

  • COVID 19 public health emergency means the period beginning on January 27, 2020 and until the termination of the national emergency concerning the COVID–19 outbreak declared pursuant to the National Emergencies Act (50 U.S.C. 1601 et seq.). 26820 Federal Register / Vol. 86, No. 93 / Monday, May 17, 2021 / Rules and Regulations Deposit means an extraordinary payment of an accrued, unfunded liability. The term deposit does not refer to routine contributions made by an employer to pension funds as part of the employer’s obligations related to payroll, such as either a pension contribution consisting of a normal cost component related to current employees or a component addressing the amortization of unfunded liabilities calculated by reference to the employer’s payroll costs. Eligible employer means an employer of an eligible worker who performs essential work. Eligible workers means workers needed to maintain continuity of operations of essential critical infrastructure sectors, including health care; emergency response; sanitation, disinfection, and cleaning work; maintenance work; grocery stores, restaurants, food production, and food delivery; pharmacy; biomedical research; behavioral health work; medical testing and diagnostics; home- and community-based health care or assistance with activities of daily living; family or child care; social services work; public health work; vital services to Tribes; any work performed by an employee of a State, local, or Tribal government; educational work, school nutrition work, and other work required to operate a school facility; laundry work; elections work; solid waste or hazardous materials management, response, and cleanup work; work requiring physical interaction with patients; dental care work; transportation and warehousing; work at hotel and commercial lodging facilities that are used for COVID–19 mitigation and containment; work in a mortuary; work in critical clinical research, development, and testing necessary for COVID–19 response.

Time is Money Join Law Insider Premium to draft better contracts faster.